Champions Oncology Balances Record Services With Margin Strain

Champions Oncology ((CSBR)) has held its Q3 earnings call. Read on for the main highlights of the call.

Champions Oncology’s latest earnings call struck a cautiously optimistic tone, highlighting record services revenue, sustained adjusted EBITDA profitability, and clear operating leverage, even as overall revenue dipped and margins compressed. Management balanced confidence in the long‑term payoff from data and Corellia with candid acknowledgment of near‑term volatility and investment‑driven pressure on profitability.

Record Services Revenue and Core Study Growth

Champions posted quarterly revenue of $16.6 million, with all of it coming from core study services and marking a record performance for that segment. Core study revenue jumped about 32% from $12.6 million a year earlier, reflecting strong execution and the conversion of previously booked work from backlog into realized sales.

Positive Adjusted EBITDA Momentum

Despite headwinds in reported revenue and margins, the company delivered its third straight quarter of positive adjusted EBITDA, reaching approximately $575,000. Management reiterated confidence in achieving positive adjusted EBITDA for the full fiscal year, underscoring a shift toward more sustainable profitability even while investing for growth.

Operating Leverage and Efficiency

The robust services growth was achieved without significant increases in headcount, showcasing tangible operating leverage in the model. This ability to scale revenue faster than staffing costs suggests room for margin expansion over time as volumes continue to rise and capacity is more fully utilized.

Early Commercial Traction in Data Business

The nascent data platform showed initial commercial traction, with a six‑figure data contract closed in the quarter and expected to be recognized in the fourth quarter. Management also anticipates incremental Q4 revenue from a previously announced large data deal, signaling growing customer interest despite current revenue lumpiness.

Strategic Investments in Growth Vectors

Champions continued to invest heavily in its data platform, including sequencing and related R&D, as well as expanding business development and commercial teams focused on data offerings. The company is also building radiopharmaceutical capabilities, positioning itself to tap into emerging oncology modalities and broaden long‑term growth drivers.

Progress at Corellia (Target Discovery Subsidiary)

Corellia, the target discovery subsidiary, is generating what management described as compelling data and receiving encouraging feedback from potential partners. The team intends to incorporate funding for Corellia into the fiscal 2027 budget while exploring external capital that could offset internal EBITDA drag and accelerate development.

Solid Balance Sheet Positioning

The company ended the quarter with $7.1 million in cash and no debt, providing financial flexibility amid ongoing investment. Net cash used in operating activities was $1.4 million for the period, which management said remained within its projected range for cash utilization.

Overall Revenue Slight Decline Year‑Over‑Year

While services hit a record, total revenue slipped about 3% year over year to $16.6 million from $17.0 million, entirely due to the absence of data revenue that had bolstered the prior period. The year‑ago quarter included approximately $4.5 million of data revenue, underscoring how timing in this newer business can distort top‑line comparisons.

Gross Margin Compression

Gross margin declined to 47% from 61% a year earlier as cost of sales climbed to $8.8 million from $6.6 million, roughly a 33% increase. More than $2 million of these costs were tied to outsourced radiolabeling work, which management noted would carry higher margins if performed internally, implying potential margin recovery as capabilities are brought in‑house.

Higher Operating Expenses

Operating expenses rose to $7.2 million from $5.3 million, an increase of about 36%, reflecting deliberate spending on future growth. The uptick was driven by R&D tied to sequencing, expanded sales and marketing for both data and services, and higher G&A related to leadership transitions and IT investments.

GAAP Loss from Operations

Despite adjusted EBITDA in positive territory, Champions reported a GAAP loss from operations of roughly $275,000 for the quarter. This gap highlights the impact of non‑adjusted items and investment spending, and it shows that the path to consistent GAAP profitability still depends on scaling revenue and improving margins.

Data Revenue Volatility and Early‑Stage Platform

The company recognized no data revenue this quarter, underscoring how early‑stage and unpredictable this business remains. Management stressed that while recent deals are encouraging, the timing and size of future data contracts may fluctuate meaningfully until the platform matures and the sales funnel becomes more predictable.

Dependency on Timing of Study Completions

Management described the business as inherently “lumpy,” with quarterly results heavily influenced by when studies complete and revenue can be recognized. Some of the quarter’s strength reflected backlog conversion that may not repeat at the same pace, cautioning investors not to over‑extrapolate short‑term swings.

Uncertain Timing for External Funding of Corellia

Although interest in Corellia from potential venture and licensing partners is growing, the timing of any external financing remains unclear. Until such a transaction is secured, Champions expects to keep funding Corellia internally, which could weigh on near‑term EBITDA even as it builds a potentially valuable asset.

Forward‑Looking Guidance and Investment Payoff

Management reaffirmed that the company remains on track for full‑year revenue growth and full‑year positive adjusted EBITDA, supported by record services performance and expected Q4 data contributions. They anticipate current investments beginning to pay off more visibly in fiscal 2027, with a more meaningful acceleration targeted for fiscal 2028, as in‑house capabilities, data monetization, and Corellia’s progress start to scale.

Champions Oncology’s call painted a picture of a company trading some near‑term profitability and margin comfort for strategic positioning in high‑value oncology services and data. For investors, the key takeaway is that record core revenue and improving operating leverage are already visible, while the ultimate upside hinges on stabilizing data revenue and unlocking value from Corellia over the next several years.